glp 1 agonist news GLP-1 drugs promise wider health benefits, but experts urge caution on use GLP-1 receptor agonists show promise

Findings: RCTSTEP 3 Trial - Wegovy vs Placebo for Weight Loss in Overweight Adults Without DM, JAMA (2021) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=611 | length = 68 weeks) in overweight or obese adults (average weight 233 lbs | average BMI 38) without diabetes Treatment: Wegovy 2.4 mg sub-q once weekly vs Placebo

Safety, Side Effects, and Personalized Monitoring As with any medication, semaglutide may have side effects, including gastrointestinal symptoms such as nausea or diarrhea, especially at the start of treatment

The LIV Body Subscription, Cancellation, and Refund Structure LIV Body's GLP-1 program is a monthly subscription, and the Terms of Use state that fees are generally non-refundable due to the nature of the services

More commonly, DPP-4 inhibitors are recommended as an option at second-line or third-line therapy in combination with metformin, when blood glucose remains inadequately controlled

At the same time, they were used as a long-term treatment option for diabetes, and the presence of insurance policies enhanced their use